Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer

Inclusion Criteria

• •Age 18 years.
• •Patients must have histologically confirmed diagnosis of non-small cell lung cancer, which is not surgically resectable (stage IA- IIIB).
• •Measurable disease.
• •Written informed consent must be obtained prior to the inclusion into the trial.
• •Karnofsky performance status of 80%.
• •Patients must have been treated with no prior chemotherapy or radioterapy.
• •Patients must have adequate bone marrow, liver and renal function.
• •* Bone Marrow: WBC \> 3000 x 103/mm3,
• •* Platelets \> 100 x 103/mm3,
• •* Hgb \> 10.0 gm/dl,
• •* ANC \>1500 x 103/mm3,
• •* Hepatic:Bilirubin \< 2 mg/dl (34 µmol/l); AST, ALT, and Alkaline Phosphatase \< 5 x normal,
• •* Renal:Creatinine \< 1.5 mg/dl (132 µmol/l).